CR20180053A - Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h. - Google Patents

Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h.

Info

Publication number
CR20180053A
CR20180053A CR20180053A CR20180053A CR20180053A CR 20180053 A CR20180053 A CR 20180053A CR 20180053 A CR20180053 A CR 20180053A CR 20180053 A CR20180053 A CR 20180053A CR 20180053 A CR20180053 A CR 20180053A
Authority
CR
Costa Rica
Prior art keywords
idh1
muted
inhibitor
adduct
isocitrate
Prior art date
Application number
CR20180053A
Other languages
English (en)
Inventor
Heiko Schirmer
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CR20180053A publication Critical patent/CR20180053A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al ácido aductivo (2E)-but-2-enedioico y ácido 3-(2-{[4-(trifluorometoxi)fenil]amino}-1-[(1R,5R)-3,3,5-trimetilciclohexil]-1H-benzimidazol-5-il)propanoico (1:4), a métodos para preparar este aducto, composiciones que comprenden este aducto y, también al uso de este aducto para preparar un medicamento para el tratamiento de una enfermedad
CR20180053A 2015-07-27 2016-07-22 Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h. CR20180053A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15178419 2015-07-27
PCT/EP2016/067477 WO2017016992A1 (en) 2015-07-27 2016-07-22 Inhibitor of the mutated isocitrate dehydrogenase idh1 r132h

Publications (1)

Publication Number Publication Date
CR20180053A true CR20180053A (es) 2018-03-20

Family

ID=53758092

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180053A CR20180053A (es) 2015-07-27 2016-07-22 Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h.

Country Status (26)

Country Link
US (1) US10344004B2 (es)
EP (1) EP3328837B1 (es)
JP (1) JP6804516B2 (es)
KR (1) KR20180030789A (es)
CN (1) CN107810181B (es)
AR (1) AR105493A1 (es)
AU (1) AU2016300980B2 (es)
BR (1) BR112018001534A2 (es)
CA (1) CA2993473A1 (es)
CL (1) CL2018000249A1 (es)
CO (1) CO2018000793A2 (es)
CR (1) CR20180053A (es)
CU (1) CU20180014A7 (es)
DO (1) DOP2018000027A (es)
EA (1) EA201890386A1 (es)
EC (1) ECSP18006465A (es)
ES (1) ES2860693T3 (es)
HK (1) HK1252449A1 (es)
IL (1) IL256024A (es)
MX (1) MX2018001205A (es)
NI (1) NI201800014A (es)
PE (1) PE20181038A1 (es)
SV (1) SV2018005621A (es)
TN (1) TN2018000038A1 (es)
TW (1) TW201708193A (es)
WO (1) WO2017016992A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031655B1 (ru) 2014-02-11 2019-02-28 Байер Фарма Акциенгезельшафт Бензимидазол-2-амины в качестве ингибиторов midhi
WO2015121209A1 (en) 2014-02-11 2015-08-20 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
US10137110B2 (en) 2014-10-23 2018-11-27 Bayer Pharma Aktiengesellschaft 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors
CA2988356A1 (en) 2015-06-08 2016-12-15 Bayer Pharma Aktiengesellschaft N-menthylbenzimidazoles as midh1 inhibitors
JP6824952B2 (ja) 2015-07-07 2021-02-03 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ ｍＩＤＨ１阻害剤としての２−アリール−および２−アリールアルキル−ベンズイミダゾール
CN108026052B (zh) 2015-07-16 2021-10-08 德国癌症研究公共权益基金会 作为mIDH1抑制剂的5-羟烷基苯并咪唑类
EP3121166A1 (en) 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法
WO2019015672A1 (zh) * 2017-07-21 2019-01-24 南京明德新药研发股份有限公司 吡啶并咪唑类化合物及其应用
EP3661559A1 (en) 2017-08-01 2020-06-10 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Combination of midh1 inhibitors and dna hypomethylating agents (hma)
CN108948205B (zh) * 2018-07-13 2021-09-28 北京金岱生物科技有限公司 抗idh1r132h单克隆抗体及其应用
TWI760017B (zh) * 2019-12-23 2022-04-01 大陸商昆藥集團股份有限公司 一種ｉｄｈ１突變體抑制劑的鹽型、晶型及其製備方法
EP4186525A4 (en) 2020-07-21 2024-04-03 Daiichi Sankyo Co Ltd COMBINATION DRUG OF TEMOZOLOMIDE AND MUTATED IDH1 ENZYME INHIBITOR

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2445345B1 (en) * 2009-06-23 2014-08-27 The Translational Genomics Research Institute Benzamide derivatives
JP5808818B2 (ja) * 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
KR20140069235A (ko) * 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
WO2015121209A1 (en) 2014-02-11 2015-08-20 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
EA031655B1 (ru) * 2014-02-11 2019-02-28 Байер Фарма Акциенгезельшафт Бензимидазол-2-амины в качестве ингибиторов midhi
US10137110B2 (en) * 2014-10-23 2018-11-27 Bayer Pharma Aktiengesellschaft 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors
CN107108522B (zh) * 2014-10-23 2020-12-01 德国癌症研究中心 作为mIDH1抑制剂的苯并咪唑-2-胺
CA2988356A1 (en) * 2015-06-08 2016-12-15 Bayer Pharma Aktiengesellschaft N-menthylbenzimidazoles as midh1 inhibitors
JP6824952B2 (ja) 2015-07-07 2021-02-03 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ ｍＩＤＨ１阻害剤としての２−アリール−および２−アリールアルキル−ベンズイミダゾール
CN108026052B (zh) 2015-07-16 2021-10-08 德国癌症研究公共权益基金会 作为mIDH1抑制剂的5-羟烷基苯并咪唑类
EP3121166A1 (en) * 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法

Also Published As

Publication number Publication date
CN107810181B (zh) 2021-06-22
JP2018521095A (ja) 2018-08-02
NI201800014A (es) 2018-09-06
TW201708193A (zh) 2017-03-01
US10344004B2 (en) 2019-07-09
ES2860693T3 (es) 2021-10-05
MX2018001205A (es) 2018-04-24
CU20180014A7 (es) 2018-06-05
WO2017016992A1 (en) 2017-02-02
CL2018000249A1 (es) 2018-07-06
AU2016300980B2 (en) 2020-12-24
EP3328837B1 (en) 2021-01-06
EP3328837A1 (en) 2018-06-06
CA2993473A1 (en) 2017-02-02
ECSP18006465A (es) 2018-04-30
CN107810181A (zh) 2018-03-16
BR112018001534A2 (pt) 2018-09-11
SV2018005621A (es) 2018-12-05
CO2018000793A2 (es) 2018-05-10
US20180222870A1 (en) 2018-08-09
HK1252449A1 (zh) 2019-05-24
AU2016300980A1 (en) 2017-12-21
TN2018000038A1 (en) 2019-07-08
DOP2018000027A (es) 2018-02-28
IL256024A (en) 2018-01-31
EA201890386A1 (ru) 2018-08-31
AR105493A1 (es) 2017-10-11
JP6804516B2 (ja) 2020-12-23
PE20181038A1 (es) 2018-07-03
KR20180030789A (ko) 2018-03-26

Similar Documents

Publication Publication Date Title
DOP2018000027A (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
CO2018006299A2 (es) Compuestos novedosos
CL2019001066A1 (es) Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854)
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
EA201790398A1 (ru) Способы лечения заболевания печени
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
UY35933A (es) Composiciones farmacéuticas que comprenden azd9291
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
ECSP14027694A (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
MY193996A (en) Tripeptide compound, preparation method therefor, and application thereof
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos
MX2017006747A (es) Amidas de acidos grasos para la prevencion y/o tratamiento de la esteatohepatitis.
CL2013002325A1 (es) Compuestos derivados de 4-amino-2-butenamidas, inhibidores de catepsina c; composicion farmaceutica que los comprende; procedimiento de preparacion de la composicion farmaceutica; uso del compuesto en el tratamiento de enfermedad pulmonar obstructiva cronica.
BR112018005843A2 (pt) inibidores de calicreína de plasma humano
CL2017000872A1 (es) Composiciones y métodos para la inhibición de la expresión génica de hao1 (hidroxiácido oxidasa 1 (glicolato oxidasa)
CU20140133A7 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
CL2016002951A1 (es) Combinación farmacéutica para el tratamiento y prevención de la hipertensión arterial y disfunción vascular